FK 866 - Daporinad | APO 866

Based on 272 publications in PubMed 10 10 272

Axon 1279

CAS [658084-64-1]

MF C24H29N3O2
MW 391.51

Purity: 99%
Soluble in 0.1N HCl(aq), DMSO, and Ethanol

FK 866

Description

Highly specific inhibitor of nicotinamide phosphoribosyltransferase (NAMPT); NAD biosynthesis inhibitor; Tumor cell apoptosis agent (see also Axon 1546)

M. Hasmann and I. Schemainda, FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis, Cancer Res. 2003, 63, 7436-7442.

A Pogrebniak et al. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur. J. Med. Res. 2006, 11(8), 313-321.

K Holen et al. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest. New Drugs. 2008, 26(1), 45-51.

List of publications using FK 866 (Axon 1279) purchased from Axon Medchem

Certificate of Analysis
Material Safety Data Sheet

Apoptosis Cell Signaling & Oncology Diabetes & Metabolism NAMPT EC 2.4.2.12

NAMPT inhibitor; NAD biosysthesis inhibitor

Chemical name

(E)-N-[4-(1-Benzoyl-piperidin-4-yl)-butyl]-3-pyridin-3-yl-acrylamide

Parent CAS No.

[658084-64-1]

產(chǎn)品資料